Clinical Data Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma BioPharma DiveInitial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) BioPharma Dive Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy. Clinical DataOncologyRead full story Post navigation Previous: FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial ResultsNext: Spyre drug for inflammatory bowel disease shows promise in early study Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
